Hikma expansion

active

Hikma Pharmaceuticals PLC (‘Hikma’, ‘the company’ or together with its subsidiaries ‘the Group’) is a generic pharmaceutical company incorporated in United Kingdom (UK) and listed on the London Stock Exchange. While the Group was founded in Jordan in 1978, Hikma has expanded its footprint with successful operations across the Middle East and North Africa (MENA) region, the United States (US) and Europe. The company has 29 manufacturing facilities in 11 countries of which facilities in 5 countries have received approval from the US Food and Drug Administration (FDA). Hikma’s main business lines include branded, injectable and generic pharmaceuticals. Hikma is a long-standing IFC client since 1987 whereby support was primarily provided to the company’s investments in the MENA region including financing of acquisition in Algeria, Tunisia and Morocco and Egypt, allied to expansion of existing facilities.  The current investment involves; i) an A Loan of up to $150 million; and ii) syndicated parallel loans of an amount to be determined to the company for general purposes of the company and members of its Group in the MENA region and other developing countries in which Hikma operates.